Sex: F
Vaccine: COVID19, COVID19
Symptoms: Decreased appetite, Dizziness, Dysgeusia, Hyperhidrosis, Insomnia
Clinical narrative: SUSPECTED COVID-19 INFECTION; SWEATING; LACK OF APPETITE; BITTER TASTE; ENHANCED TASTE; SLEEPLESSNESS; LIGHTHEADEDNESS; STOMACH REJECTED IT THREW UP IN A FEW MINUTES; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a 62 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: depression, anorexia nervosa, osteoporosis, osteoarthritis, and allergy, and other pre-existing medical conditions included: The patient was not pregnant at the time of report. The patient previously received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, batch number, and expiry were not reported) 1 in total, dose was not reported administered on 05-MAY-2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1). The patient additionally received covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin, batch number, and expiry were not reported) 1 in total, dose was not reported administered on 08-DEC-2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 2). The batch number was not reported and has been requested. The patient additionally received non-company suspect vaccine included: Pfizer BioNtech covid-19 vaccine (tozinameran) (dose number in series 3) (Form of admin, route of admin, batch number, and expiry were not reported) dose was not reported, administered on 25-MAY-2022 for covid-19 prophylaxis. Concomitant medications included alendronate sodium, citalopram, terbinafine, and trazodone.  On an unspecified date, the patient experienced covid-19 infection (coded as suspected covid-19 infection) (dose number in series 3). The patient received non-company co-suspect drug Paxlovid (form of administration, route of administration not reported, batch number: FX8133, and expiry: UNKNOWN) dose was not reported, administered from 06-JUL-2022 to 10-JUL-2022 for treatment of COVID-19. The patient was not receiving any other medications/products within 2 weeks of starting COVID-19 treatment. On 07-JUL-2022, the patient experienced sweating, lack of appetite, bitter taste, enhanced taste, sleeplessness, and lightheadedness (dose number in series 3). When the patient started the fifth dose her stomach rejected it. The patient threw up in a few minutes, her doctor told her to stop taking Trazadone during the treatment since it was on the list of drugs that conflict with Paxlovid. The action taken with covid-19 vaccine ad26.cov2.s was not applicable, Pfizer BioNtech covid-19 vaccine (tozinameran) was not applicable and with paxlovid was drug discontinued. The patient recovered from sweating, lack of appetite, bitter taste, enhanced taste, sleeplessness, lightheadedness, and stomach rejected it threw up in a few minutes on 10-JUL-2022, and the outcome of suspected covid-19 infection was not reported. This report was non-serious.